RTS,S
| Vaccine description | |
|---|---|
| Target | P. falciparum; to a lesser extent Hepatitis B |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Mosquirix |
| Routes of administration | intramuscular injection (0.5 mL) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. 18 million doses have been allocated for 2023–2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.